Download this free whitepaper to learn more.
The rapid expansion of monoclonal antibody (mAb) therapeutics has intensified pressure on biopharmaceutical developers to improve productivity, cost efficiency, and supply reliability while maintaining stringent quality standards. Conventional batch-based manufacturing models continue to present challenges related to scale-dependent capital investment, facility utilization, process variability, and operational flexibility. Increasingly, continuous manufacturing approaches are being explored as a way to integrate upstream and downstream unit operations into more coordinated production workflows supported by real-time monitoring and advanced process control.
This whitepaper provides a comprehensive technical, economic, and regulatory framework for implementing continuous manufacturing strategies in mAb production. It examines practical considerations associated with process integration, operational scalability, lifecycle management, and regulatory readiness, while outlining approaches organizations can use to evaluate adoption within existing manufacturing environments.
Access now to explore:
- Process architecture, robustness, and control considerations
- Quantitative factors influencing cost of goods, facility footprint, and scalability
- Practical considerations for technology adoption and lifecycle management
- Current regulatory perspectives on continuous biomanufacturing
- Operational and organizational considerations for transitioning from batch-based to continuous production models
Through an evidence-based analysis informed by commercial manufacturing experience, you’ll discover how continuous manufacturing approaches may support more scalable, compliant, and economically sustainable biologics production over the long term. Download today!
Offered Free by: Enzene
See All Resources from: Enzene
